logo-loader
viewMotif Bio PLC

Motif Bio meets FDA

The company expects to be furnished with minutes from its meeting in the next 30 days, allowing it to chart a path for its lead drug

1557211409_FDA.jpg
The company met with US regulatory authorities

Motif Bio PLC (LON:MTFB, NASDAQ:MTFB) is expected to be able to chart a “path forward” for its lead drug iclaprim in the next month after a meeting with the US regulator went ahead as planned.

The company sought talks after the Food & Drug Administration declined to give the antibiotic the green light, citing in a document the need for additional data on liver toxicity.

As one of Motif’s advisers pointed out, this wasn’t a straight ‘no’.The firm has always said it was keen to discuss potential deficiencies with the information provided.

The latest meeting offered that chance, with feedback expected in the next 30 days.

“After Motif Bio has received the [FDA’s] minutes, the company will be in a position to provide an update to the market on the path forward for iclaprim,” the company said in a short investor update.

iclaprim is being developed as a treatment for acute skin infection.

Quick facts: Motif Bio PLC

Price: 0.47998 GBX

AIM:MTFB
Market: AIM
Market Cap: £1.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: AfriTin Mining produces first concentrate from Uis mine

Headlines from the Proactive UK newsroom. AfriTin Mining (LON:ATM) has produced is first tin concentrate from the Uis mine in Namibia. The miner has also signed an offtake deal with a Thai group.  BlueRock Diamonds (LON:BRD) has sold a fifth diamond this year for more than US$50,000....

on 19/8/19

RNS

Directorate Changes

2 hours, 43 minutes ago

Result of General Meeting

3 days, 20 hours ago

Holding(s) in Company

3 weeks ago

Holding(s) in Company

3 weeks, 3 days ago

Second Price Monitoring Extn

3 weeks, 3 days ago

Price Monitoring Extension

3 weeks, 3 days ago

2 min read